8-K: Compass Therapeutics Updates Q3 2025 Results, Clinical Pipeline

Compass Therapeutics reported third quarter 2025 financial results and provided key updates on its clinical pipeline, including delayed data readouts for tovecimig and CTX-8371, and a strong cash position.

Summary

• Net loss for the quarter ended September 30, 2025, was $14.3 million, or $0.08 per share, compared to $10.5 million, or $0.08 per share, for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $50.8 million, or $0.34 per share, compared to $34.3 million, or $0.25 per share, for the same period in 2024.
• Research and Development (R&D) expenses increased by 49% to $12.8 million for Q3 2025, primarily due to $4.2 million in manufacturing and IND-enabling costs for CTX-10726.
• General and Administrative (G&A) expenses decreased by 18% to $3.0 million for Q3 2025, mainly due to a $1.1 million credit from the return of unvested employee equity, partially offset by increased market research costs.
• Cash and marketable securities totaled $220 million as of September 30, 2025, which is expected to provide a cash runway into 2028.
• Analyses of overall survival (OS) and progression-free survival (PFS) for tovecimig in the Phase 2/3 COMPANION-002 study are now expected in late Q1 2026, based on a continuing trend of decreased mortality.
• A new response in a third indication was observed in the fifth and final dosing cohort of the Phase 1 study of CTX-8371, with no dose-limiting toxicities observed at any dose level.
• Full topline data for the CTX-8371 Phase 1 study are now expected to be presented at a medical meeting in H1 2026.
• Cohort expansions for CTX-8371 in patients with non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC) are expected to begin in Q4 2025.
• The Investigational New Drug (IND) filing for CTX-10726 is planned for Q4 2025, with initial Phase 1 clinical data expected in H2 2026.
• A Phase 2 trial of CTX-471 in patients with tumors expressing NCAM (CD56) is expected to initiate in Q1 2026.

Sentiment

Score: 6

Explanation: While the filing indicates increased net losses and delays in key clinical data readouts for tovecimig and CTX-8371, these are partially offset by a strong cash position extending into 2028, successful financing, and promising early clinical and preclinical data for its pipeline assets, particularly CTX-8371's differentiated safety profile and CTX-10726's superior preclinical performance against a competitor. The long-term potential remains, but the short-term delays and increased burn rate introduce some caution.

Positives

• Cash and marketable securities of $220 million as of September 30, 2025, are expected to provide a cash runway into 2028.
• The company completed an upsized and oversubscribed $138 million financing in August, including the full exercise of the over-allotment option, attracting top-tier, healthcare-focused investors.
• Tovecimig met its primary endpoint (overall response rate) in the COMPANION-002 Phase 2/3 study in April 2025.
• A continuing trend of decreased mortality has been observed in the ongoing Phase 2/3 COMPANION-002 study of tovecimig.
• CTX-8371 Phase 1 study observed a new response in a third indication in the final dosing cohort and no dose-limiting toxicities at any dose level, suggesting a differentiated safety profile.
• CTX-8371 previously reported deep partial responses in patients with NSCLC and TNBC.
• CTX-10726 demonstrated superior tumor control compared to ivonescimab in head-to-head studies with a human NSCLC xenograft mouse model.
• CTX-10726 showed superior PD-1 inhibition in head-to-head studies with a mouse model of PD-1 blockade and more potent PD-1 blockade in in vitro studies.

Negatives

• Net loss for the quarter ended September 30, 2025, increased to $14.3 million from $10.5 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, increased to $50.8 million from $34.3 million in the prior year period.
• Research and Development (R&D) expenses increased significantly by 49% in Q3 2025 and 44% for the nine months ended September 30, 2025, primarily due to manufacturing and IND-enabling costs.
• Operating activities used $35.9 million of net cash during the first nine months of 2025.

Risks

• Ability to raise additional funding needed to continue pursuing business and product development plans.
• Inherent uncertainties associated with developing product candidates and operating as a development stage company.
• Ability to identify additional product candidates for development.
• Ability to develop, initiate and complete clinical trials for, obtain approvals for and commercialize any product candidates.
• Competition in the industry in which the company operates.
• Market conditions.

Future Outlook

Compass Therapeutics anticipates reporting top-line OS and PFS data for tovecimig in late Q1 2026, which could support a Biologics License Application (BLA) filing in the second half of 2026. Cohort expansions for CTX-8371 in NSCLC and TNBC are expected to commence in Q4 2025, with full Phase 1 data presentation in H1 2026. The company plans an IND filing for CTX-10726 in Q4 2025, targeting initial Phase 1 clinical data in H2 2026. A Phase 2 trial for CTX-471 is slated for Q1 2026. The current cash and marketable securities are projected to provide a cash runway into 2028.

Management Comments

• "We have made strong progress across our clinical pipeline this quarter and based on a continuing trend of lower mortality in the ongoing randomized trial of tovecimig in patients with advanced BTC, we expect to report the OS and PFS data in late Q1 2026."
• "These secondary endpoint data will build on the statistically significant primary endpoint of overall response rate we previously reported, and we expect could support our first BLA filing in the second half of 2026."
• "Recent claims-based market research shows ~25,000 patients are diagnosed with BTC annually in the United States alone, and tovecimig could provide hope for the vast majority of patients in the second line who have no approved therapeutic option."
• "Importantly, we have also observed a new response in an additional indication in the fifth and final dosing cohort of CTX-8371, which is now fully enrolled, in patients treated in the post-checkpoint inhibitor setting."
• "There have been no dose-limiting toxicities (DLTs) observed at any dose level, suggesting that CTX-8371 may have a differentiated safety profile."
• "All these plans are fully supported by our upsized and oversubscribed $138 million financing, which included full exercise of the over-allotment option, that we announced in August."

Industry Context

The company operates in the highly competitive oncology biopharmaceutical sector, focusing on developing proprietary antibody-based therapeutics. Its pipeline, featuring bispecific antibodies targeting pathways like DLL4, VEGF-A, PD-1, and PD-L1, aligns with the industry's trend towards multi-target approaches to enhance anti-tumor responses and overcome resistance. The emphasis on advanced biliary tract cancer (BTC) addresses a significant unmet medical need, particularly for second-line patients with limited approved options. The preclinical superiority of CTX-10726 against a competitor like ivonescimab highlights the company's efforts to differentiate its candidates in a crowded market for immune-oncology agents.

Comparison to Industry Standards

• CTX-10726 demonstrated superior tumor control compared to ivonescimab in head-to-head studies using a human NSCLC (HCC827) xenograft mouse model.
• CTX-10726 showed superior PD-1 inhibition in head-to-head studies with a mouse (MC38) model of PD-1 blockade.
• CTX-10726 exhibited more potent PD-1 blockade in in vitro studies compared to ivonescimab.
• The absence of dose-limiting toxicities (DLTs) observed at any dose level for CTX-8371 potentially differentiates it from current checkpoint inhibitors, suggesting a more favorable safety profile.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through pipeline advancement, but short-term uncertainty due to delayed data readouts and increased losses. The strong cash position provides financial stability.
• Patients: Hope for new therapeutic options, especially in advanced biliary tract cancer where options are limited, and for NSCLC and TNBC with promising early CTX-8371 data.
• Employees: Continued focus on clinical development and potential for future growth and stability due to extended cash runway.
• Creditors/Suppliers: Stable financial position with an anticipated cash runway into 2028, indicating good liquidity.

Next Steps

• Begin CTX-8371 cohort expansions in NSCLC and TNBC in Q4 2025.
• File IND for CTX-10726 in Q4 2025.
• Initiate Phase 2 trial of CTX-471 in Q1 2026.
• Report top-line OS and PFS data for tovecimig in late Q1 2026.
• Present full topline data from CTX-8371 Phase 1 study at a medical meeting in H1 2026.
• Present preclinical data for CTX-10726 at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting this week.
• Expect initial Phase 1 clinical data for CTX-10726 in H2 2026.
• Potentially file Biologics License Application (BLA) for tovecimig in the second half of 2026.
• Prepare for a Phase 2 basket study of tovecimig in a broader set of patients with DLL4+ cancers following a comprehensive analysis of the complete data set from the COMPANION-002 BTC trial.
• Continue active enrollment for the investigator sponsored trial (IST) of tovecimig in combination with gemcitabine, cisplatin, and durvalumab.

Key Dates

Recommendation

While the company reported increased net losses and delays in key clinical data readouts for tovecimig and CTX-8371, these are partially offset by a strong cash position extending into 2028, successful financing, and promising early clinical and preclinical data for its pipeline assets, particularly CTX-8371's differentiated safety profile and CTX-10726's superior preclinical performance against a competitor. The long-term potential remains, but the short-term delays and increased burn rate warrant a cautious "hold" stance until more definitive clinical outcomes are available.

Keywords

Oncology, Biopharmaceutical, Clinical-stage, Antibody therapeutics, Tovecimig, DLL4, VEGF-A, Biliary tract cancer, BTC, COMPANION-002, CTX-8371, PD-1, PD-L1, Non-small cell lung cancer, NSCLC, Triple-negative breast cancer, TNBC, CTX-10726, CTX-471, CD137, Cancer treatment, Clinical trials, Financial results, Cash runway, SEC filing